A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab

BACKGROUND: Anti-CTLA-4 immune checkpoint blockade is associated with immune-related adverse events (irAEs). Grade 3–4 diarrhea/colitis is the most frequent irAE requiring treatment discontinuation. Predicting high-risk diarrhea/colitis patients may facilitate early intervention, limit irAE severity...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedlander, Philip, Wood, Kevin, Wassmann, Karl, Christenfeld, Alan M., Bhardwaj, Nina, Oh, William K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145108/
https://www.ncbi.nlm.nih.gov/pubmed/30227886
http://dx.doi.org/10.1186/s40425-018-0408-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145108/
https://www.ncbi.nlm.nih.gov/pubmed/30227886
http://dx.doi.org/10.1186/s40425-018-0408-9

Ejemplares similares